<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792633</url>
  </required_header>
  <id_info>
    <org_study_id>831916</org_study_id>
    <secondary_id>18CT014</secondary_id>
    <nct_id>NCT03792633</nct_id>
  </id_info>
  <brief_title>Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL</brief_title>
  <official_title>Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19&#xD;
      cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This&#xD;
      study is targeting pediatric and young adult patients aged 1-29 years with CD19+ B cell&#xD;
      malignancies in newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome&#xD;
      with conventional chemotherapy, in high-risk first relapse, or and in second or greater&#xD;
      relapse in this phase 2 trial. In addition, a second cohort will test the efficacy of&#xD;
      huCART19 in patients with poor response to prior B cell directed engineered cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Event-Free Survival in patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year Event-Free Survival in patients with poor response to prior B cell directed engineered cell therapy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Newly Diagnosed VHR B-ALL or High-Risk Relapse of B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor Response to Prior B Cell Directed Engineered cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>huCART19</intervention_name>
    <description>huCART19 infusion</description>
    <arm_group_label>Newly Diagnosed VHR B-ALL or High-Risk Relapse of B</arm_group_label>
    <arm_group_label>Poor Response to Prior B Cell Directed Engineered cell therapy</arm_group_label>
    <other_name>huCTL019</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Relapsed or refractory B-cell ALL:&#xD;
&#xD;
          -  Cohort A: Patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL who&#xD;
             meet one of the following criteria:&#xD;
&#xD;
               -  Newly diagnosed NCI HR B-ALL with induction failure: M3 marrow (&gt;25% blasts) at&#xD;
                  end of induction OR&#xD;
&#xD;
               -  First marrow relapse of B-ALL at &lt; 36 months from diagnosis OR&#xD;
&#xD;
               -  2nd or greater relapse OR&#xD;
&#xD;
               -  Any relapse after allogeneic hematopoietic stem cell transplantation (HSCT) and ≥&#xD;
                  4 months from stem cell transplant (SCT) at enrollment OR&#xD;
&#xD;
               -  Refractory disease defined as having not achieved a minimal residual disease&#xD;
                  (MRD)_-negative and/or cerebral spinal fluid (CSF)-negative complete response&#xD;
                  (CR) after ≥ 2 chemotherapy regimens/cycles of frontline therapy or 1 cycle of&#xD;
                  reinduction therapy for patients in first relapse OR&#xD;
&#xD;
               -  Ineligible for allogeneic stem cell transplant&#xD;
&#xD;
          -  Cohort B: Patients previously treated with B cell directed engineered cell therapy who&#xD;
             meet one of the following criteria:&#xD;
&#xD;
               -  partial response or no response to prior cell therapy&#xD;
&#xD;
               -  CD19+ relapse after prior cell therapy&#xD;
&#xD;
               -  demonstrated early (≤6 months from infusion) B cell recovery suggesting loss of&#xD;
                  engineered cells&#xD;
&#xD;
          -  Patients with prior or current history of CNS3 disease will be eligible if central&#xD;
             nervous system (CNS) disease is responsive to therapy&#xD;
&#xD;
          -  Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor&#xD;
             tissue by flow cytometry at relapse&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Age 1-29 years&#xD;
&#xD;
          -  Adequate performance status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis B or active hepatitis C.&#xD;
&#xD;
          -  HIV Infection.&#xD;
&#xD;
          -  Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.&#xD;
&#xD;
          -  Concurrent use of systemic steroids at the time of cell infusion or cell collection,&#xD;
             or a condition, in the treating physician's opinion, that is likely to require steroid&#xD;
             therapy during collection or after infusion. Steroids for disease treatment at times&#xD;
             other than cell collection or at the time of infusion are permitted. Use of&#xD;
             physiologic replacement hydrocortisone or inhaled steroids is permitted as well.&#xD;
&#xD;
          -  CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that&#xD;
             might increase the risk of CNS toxicity.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon Maude, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mia Benson-Smith</last_name>
    <phone>267-426-0762</phone>
    <email>oncointake@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire White</last_name>
    <email>whiteC3@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

